{"disease":{"id":"platinum-sensitive-relapsed-ovarian-cancer","name":"platinum sensitive relapsed ovarian cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01874353","title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":327,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03705156","title":"Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":265,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT04861181","title":"NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}